These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38977798)

  • 1. Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.
    Yasutake Y; Hattori SI; Kumamoto H; Tamura N; Maeda K; Mitsuya H
    Sci Rep; 2024 Jul; 14(1):15742. PubMed ID: 38977798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
    Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
    J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
    Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
    Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
    Yasutake Y; Hattori SI; Hayashi H; Matsuda K; Tamura N; Kohgo S; Maeda K; Mitsuya H
    Sci Rep; 2018 Jan; 8(1):1624. PubMed ID: 29374261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
    Higashi-Kuwata N; Hayashi S; Kumamoto H; Ogata-Aoki H; Das D; Venzon D; Hattori SI; Bulut H; Hashimoto M; Otagiri M; Takamune N; Kishimoto N; Davis DA; Misumi S; Kakuni M; Tanaka Y; Mitsuya H
    J Hepatol; 2021 May; 74(5):1075-1086. PubMed ID: 33333207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors.
    Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
    Biochem Biophys Res Commun; 2019 Feb; 509(4):943-948. PubMed ID: 30648556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
    Walsh AW; Langley DR; Colonno RJ; Tenney DJ
    PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.
    Nakamura A; Tamura N; Yasutake Y
    Acta Crystallogr F Struct Biol Commun; 2015 Nov; 71(Pt 11):1384-90. PubMed ID: 26527265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
    Das K; Martinez SE; Arnold E
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
    Choo H; Chong Y; Chu CK
    Bioorg Med Chem Lett; 2003 Jun; 13(12):1993-6. PubMed ID: 12781181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
    Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
    Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
    J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
    Rawal RK; Konreddy AK; Chu CK
    Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
    J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.